| Dr Daniel Edward Cason, MD | |
|
100 E Carroll St, Salisbury, MD 21801 | |
| (410) 749-1124 | |
| (410) 749-1270 |
| Full Name | Dr Daniel Edward Cason |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 11 Years |
| Location | 100 E Carroll St, Salisbury, Maryland |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386986172 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Peninsula Regional Medical Center | Salisbury, MD | Hospital |
| Nanticoke Memorial Hospital | Seaford, DE | Hospital |
| Atlantic General Hospital | Berlin, MD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Peninsula Imaging Llc | 7810968286 | 15 |
| Delmarva Radiology P A | 9638068547 | 15 |
| Delmarva Radiology P A | 9638068547 | 15 |
News Archive
On Wednesday, July 15, 2020, the Dietary Guidelines Advisory Committee (DGAC or Committee) - a group comprised of 20 nationally recognized health and nutrition experts - published the Scientific Report of the 2020 Dietary Guidelines Advisory Committee: Advisory Report to the Secretary of Agriculture and the Secretary of Health and Human Services.
A few years from now millions of people around the world might be walking around with an unusual kind of glass in their mouth, and using it every time they eat.
Researchers at UCLA's Jonsson Comprehensive Cancer Center have discovered a new cell signaling pathway that controls cell growth and development, a pathway that, when defective, helps promote the formation of several major forms of human cancer, including lymphoma and leukemia.
New IMBRUVICA (ibrutinib) Phase II data announced by Pharmacyclics, Inc. today demonstrates its potential utility as a combination therapy when used with rituximab. Data suggest that the overall efficacy and safety profile of IMBRUVICA is well tolerated when combined with rituximab in patients with relapsed or refractory mantle cell lymphoma (MCL).
› Verified 6 days ago
| Entity Name | Johns Hopkins University |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922008549 PECOS PAC ID: 8921903147 Enrollment ID: O20031215000719 |
News Archive
On Wednesday, July 15, 2020, the Dietary Guidelines Advisory Committee (DGAC or Committee) - a group comprised of 20 nationally recognized health and nutrition experts - published the Scientific Report of the 2020 Dietary Guidelines Advisory Committee: Advisory Report to the Secretary of Agriculture and the Secretary of Health and Human Services.
A few years from now millions of people around the world might be walking around with an unusual kind of glass in their mouth, and using it every time they eat.
Researchers at UCLA's Jonsson Comprehensive Cancer Center have discovered a new cell signaling pathway that controls cell growth and development, a pathway that, when defective, helps promote the formation of several major forms of human cancer, including lymphoma and leukemia.
New IMBRUVICA (ibrutinib) Phase II data announced by Pharmacyclics, Inc. today demonstrates its potential utility as a combination therapy when used with rituximab. Data suggest that the overall efficacy and safety profile of IMBRUVICA is well tolerated when combined with rituximab in patients with relapsed or refractory mantle cell lymphoma (MCL).
› Verified 6 days ago
| Entity Name | Delmarva Radiology P A |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1699733527 PECOS PAC ID: 9638068547 Enrollment ID: O20040310001320 |
News Archive
On Wednesday, July 15, 2020, the Dietary Guidelines Advisory Committee (DGAC or Committee) - a group comprised of 20 nationally recognized health and nutrition experts - published the Scientific Report of the 2020 Dietary Guidelines Advisory Committee: Advisory Report to the Secretary of Agriculture and the Secretary of Health and Human Services.
A few years from now millions of people around the world might be walking around with an unusual kind of glass in their mouth, and using it every time they eat.
Researchers at UCLA's Jonsson Comprehensive Cancer Center have discovered a new cell signaling pathway that controls cell growth and development, a pathway that, when defective, helps promote the formation of several major forms of human cancer, including lymphoma and leukemia.
New IMBRUVICA (ibrutinib) Phase II data announced by Pharmacyclics, Inc. today demonstrates its potential utility as a combination therapy when used with rituximab. Data suggest that the overall efficacy and safety profile of IMBRUVICA is well tolerated when combined with rituximab in patients with relapsed or refractory mantle cell lymphoma (MCL).
› Verified 6 days ago
| Entity Name | Peninsula Imaging Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851359707 PECOS PAC ID: 7810968286 Enrollment ID: O20040802000559 |
News Archive
On Wednesday, July 15, 2020, the Dietary Guidelines Advisory Committee (DGAC or Committee) - a group comprised of 20 nationally recognized health and nutrition experts - published the Scientific Report of the 2020 Dietary Guidelines Advisory Committee: Advisory Report to the Secretary of Agriculture and the Secretary of Health and Human Services.
A few years from now millions of people around the world might be walking around with an unusual kind of glass in their mouth, and using it every time they eat.
Researchers at UCLA's Jonsson Comprehensive Cancer Center have discovered a new cell signaling pathway that controls cell growth and development, a pathway that, when defective, helps promote the formation of several major forms of human cancer, including lymphoma and leukemia.
New IMBRUVICA (ibrutinib) Phase II data announced by Pharmacyclics, Inc. today demonstrates its potential utility as a combination therapy when used with rituximab. Data suggest that the overall efficacy and safety profile of IMBRUVICA is well tolerated when combined with rituximab in patients with relapsed or refractory mantle cell lymphoma (MCL).
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Daniel Edward Cason, MD 918 Eastern Shore Dr, Salisbury, MD 21804-6410 Ph: (410) 749-1124 | Dr Daniel Edward Cason, MD 100 E Carroll St, Salisbury, MD 21801 Ph: (410) 749-1124 |
News Archive
On Wednesday, July 15, 2020, the Dietary Guidelines Advisory Committee (DGAC or Committee) - a group comprised of 20 nationally recognized health and nutrition experts - published the Scientific Report of the 2020 Dietary Guidelines Advisory Committee: Advisory Report to the Secretary of Agriculture and the Secretary of Health and Human Services.
A few years from now millions of people around the world might be walking around with an unusual kind of glass in their mouth, and using it every time they eat.
Researchers at UCLA's Jonsson Comprehensive Cancer Center have discovered a new cell signaling pathway that controls cell growth and development, a pathway that, when defective, helps promote the formation of several major forms of human cancer, including lymphoma and leukemia.
New IMBRUVICA (ibrutinib) Phase II data announced by Pharmacyclics, Inc. today demonstrates its potential utility as a combination therapy when used with rituximab. Data suggest that the overall efficacy and safety profile of IMBRUVICA is well tolerated when combined with rituximab in patients with relapsed or refractory mantle cell lymphoma (MCL).
› Verified 6 days ago
Gerard Joseph Hogan, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 100 E Carroll St, Salisbury, MD 21801 Phone: 410-749-1124 Fax: 410-749-1270 | |
Dr. William K Woods, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 100 E Carroll St, Salisbury, MD 21801 Phone: 410-543-7000 Fax: 410-543-7018 | |
Simmi Chawla, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 100 E Carroll St, Salisbury, MD 21801 Phone: 410-677-6656 Fax: 410-749-1270 | |
Peter Alfred Libby, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 100 E Carroll St, Salisbury, MD 21801 Phone: 410-749-1124 Fax: 410-749-1270 | |
Alexander Joseph Zito, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 100 E Carroll St, Salisbury, MD 21801 Phone: 410-543-7370 Fax: 410-749-1270 | |
Thomas Joseph Riccio, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 100 E Carroll St, Salisbury, MD 21801 Phone: 410-749-1124 Fax: 410-749-1270 |